Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

Phase 1 single dose already came out and was positive usual 30 to 50% reduction of scarring and no negative effect on the wound healing process. That's important not only to stop scar formation but not to block the process entirely. So positive news.

phase 1 multi dose is the next catalyst on deck and will be reported and the analyst and investor Symposium held by RXII. They will discuss phase 1 multi dose results and phase 2 trial design. Also other members will talk about other ocular conditions they are targeting: macular degeneration, diabetic enema, PVR, Retinoblastoma(eye cancer in children) etc.